Besides, in specific cancers (e.g., BLCA and CRC) and in distinct clinical settings (e.g., age > 60, male gender, high TMB, and anti-PD-1/PD-L1 treatment), patients with DDR mutations also exhibited the ICB survival benefits. The gene discussed is PDCD1; the disease is bladder transitional cell carcinoma.